• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿激酶型纤溶酶原激活剂氨基末端肽抑制大鼠腹侧前列腺的发育。

Urokinase plasminogen activator amino-terminal peptides inhibit development of the rat ventral prostate.

作者信息

Elfman F, Bok R, Conn M, Shuman M, Cunha G

机构信息

Department of Anatomy, University of California, San Francisco 94143, USA.

出版信息

Differentiation. 2001 Dec;69(2-3):108-20. doi: 10.1046/j.1432-0436.2001.690205.x.

DOI:10.1046/j.1432-0436.2001.690205.x
PMID:11798065
Abstract

The plasma membrane urokinase plasminogen activator receptor (uPAR) localizes and enhances activation of pro-uPA. Active uPA, in turn, promotes increased degradation of the extracellular matrix (ECM) by activation of plasminogen. uPAR binds to ECM molecules and integrins, which can affect cellular adhesion, signal transduction, and gene regulation. The current study examines the expression and function of uPAR in developing rat ventral prostates (VPs). We report that newborn VPs express uPAR mRNA and protein. In addition, the function of uPAR-bound uPA during in vitro prostatic development was studied by adding recombinant peptide competitive inhibitors of uPA-uPAR binding. Newborn VP explants were cultured in serum-free media for one week with 10(-8) M testosterone plus chimeric peptides containing a human immunoglobulin G Fc domain and either human uPA amino acids 1-138 (hu-uPA 1-138) as a control or mouse uPA amino acids 1-138 (mo-uPA 1-138) or 1-48 (mo-uPA 1-48). Hu-uPA 1-138-treated VPs underwent normal ductal branching morphogenesis and tissue differentiation. In contrast, VPs treated with mo-uPA 1-138 or mo-uPA 1-48 displayed a dose-dependent perturbation of ductal branching. Differentiation of both epithelial and mesenchymal tissues was also impaired. Mo-uPA 1-48-treated VPs contained significantly more apoptotic cells. These observations suggest that disruption of uPA binding to uPAR results in a retardation of the development of newborn VPs.

摘要

质膜尿激酶型纤溶酶原激活物受体(uPAR)可使尿激酶原(pro - uPA)定位并增强其激活作用。反过来,活性尿激酶型纤溶酶原激活物(uPA)通过激活纤溶酶原促进细胞外基质(ECM)降解增加。uPAR与ECM分子及整合素结合,这会影响细胞黏附、信号转导和基因调控。本研究检测了uPAR在发育中的大鼠腹侧前列腺(VP)中的表达及功能。我们发现新生VP表达uPAR mRNA和蛋白。此外,通过添加uPA - uPAR结合的重组肽竞争性抑制剂,研究了uPAR结合的uPA在体外前列腺发育过程中的功能。将新生VP外植体在无血清培养基中培养一周,培养基中含有10⁻⁸ M睾酮以及嵌合肽,该嵌合肽含有人类免疫球蛋白G Fc结构域以及作为对照的人uPA氨基酸1 - 138(hu - uPA 1 - 138)或小鼠uPA氨基酸1 - 138(mo - uPA 1 - 138)或1 - 48(mo - uPA 1 - 48)。经hu - uPA 1 - 138处理的VP经历了正常的导管分支形态发生和组织分化。相反,经mo - uPA 1 - 138或mo - uPA 1 - 48处理的VP表现出导管分支的剂量依赖性扰动。上皮和间充质组织的分化也受到损害。经mo - uPA 1 - 48处理的VP含有明显更多的凋亡细胞。这些观察结果表明,uPA与uPAR结合的破坏导致新生VP发育迟缓。

相似文献

1
Urokinase plasminogen activator amino-terminal peptides inhibit development of the rat ventral prostate.尿激酶型纤溶酶原激活剂氨基末端肽抑制大鼠腹侧前列腺的发育。
Differentiation. 2001 Dec;69(2-3):108-20. doi: 10.1046/j.1432-0436.2001.690205.x.
2
Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.尿激酶型纤溶酶原激活物受体(uPAR)在血液和骨髓细胞上的结构、功能及表达
Stem Cells. 1997;15(6):398-408. doi: 10.1002/stem.150398.
3
Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.尿激酶型纤溶酶原激活剂和尿激酶型纤溶酶原激活剂受体介导人干细胞对恶性实体瘤的趋向性。
Stem Cells. 2008 Jun;26(6):1406-13. doi: 10.1634/stemcells.2008-0141. Epub 2008 Apr 10.
4
Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.在基因缺陷小鼠中产生的抗小鼠尿激酶型纤溶酶原激活物受体的鼠单克隆抗体:对体内外受体介导的尿激酶型纤溶酶原激活物活性的抑制作用
Thromb Haemost. 2007 Jun;97(6):1013-22.
5
Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).环[19,31][D-半胱氨酸19]-尿激酶型纤溶酶原激活剂19-31是尿激酶型纤溶酶原激活剂与其受体(CD87)相互作用的强效竞争性拮抗剂。
Biol Chem. 2001 Aug;382(8):1197-205. doi: 10.1515/BC.2001.150.
6
Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.尿激酶型纤溶酶原激活剂及其受体在人肾细胞癌中的差异基因表达
Oncol Rep. 2005 Sep;14(3):777-82.
7
Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.稳定表达尿激酶型纤溶酶原激活剂氨基末端片段的人胶质母细胞瘤细胞侵袭特性的调节
Oncogene. 2002 Nov 7;21(51):7824-30. doi: 10.1038/sj.onc.1205893.
8
Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.利用单克隆抗体鉴别细胞表面小鼠尿激酶型纤溶酶原激活物受体的不同形式
J Immunol Methods. 2008 Nov 30;339(1):55-65. doi: 10.1016/j.jim.2008.08.002. Epub 2008 Aug 30.
9
In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.尿激酶型纤溶酶原激活剂及其受体在人膀胱移行细胞癌中的原位基因表达
Oncol Rep. 2004 Oct;12(4):909-13.
10
Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion.Heregulin对尿激酶型纤溶酶原激活剂及其受体的调控:人乳腺上皮细胞侵袭
Cancer Res. 2001 Jan 1;61(1):400-5.